Zevra Therapeutics, Inc. Amortization of Debt Issuance Costs
Zevra Therapeutics, Inc. (ZVRA) reported Amortization of Debt Issuance Costs of $1.92 million for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2019-08-13
- Zevra Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2019-06-30 was $1.06M, a 9.28% decline year-over-year.
- Zevra Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2019-03-31 was $863.00K, a 16.29% decline year-over-year.
- Zevra Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2018-12-31 was $966.00K, a 18.55% decline year-over-year.
- Zevra Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2018-09-30 was -$1.07M.
- Zevra Therapeutics, Inc. amortization of debt issuance costs for fiscal 2018 was $2.09M, a 5.99% decline from fiscal 2017.
- Zevra Therapeutics, Inc. amortization of debt issuance costs for fiscal 2017 was $2.22M, a 0.00% change from fiscal 2016.
- Zevra Therapeutics, Inc. amortization of debt issuance costs for fiscal 2016 was $2.22M, a 16.81% decline from fiscal 2015.
- Zevra Therapeutics, Inc. amortization of debt issuance costs for fiscal 2015 was $2.67M, a 66.73% increase from fiscal 2014.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2019-06-30 | $1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $1.92M 10-Q · filed 2019-08-13 | $2.88M derived: sum of 3 quarters · filed 2019-08-13 | $1.81M derived: sum of 4 quarters · filed 2019-08-13 |
| 2019-03-31 | $863.00K 10-Q · filed 2019-05-14 | $1.83M derived: sum of 2 quarters · filed 2019-05-14 | $757.00K derived: sum of 3 quarters · filed 2019-05-14 | $1.92M derived: sum of 4 quarters · filed 2019-08-13 |
| 2018-12-31 | $966.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | -$106.00K derived: sum of 2 quarters · filed 2019-03-01 | $1.06M derived: sum of 3 quarters · filed 2019-08-13 | $2.09M 10-K · filed 2019-03-01 |
| 2018-09-30 | -$1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $92.00K derived: sum of 2 quarters · filed 2019-08-13 | $1.12M 10-Q · filed 2018-11-09 | $2.31M derived: sum of 4 quarters · filed 2019-08-13 |
| 2018-06-30 | $1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $2.19M 10-Q · filed 2019-08-13 | $3.38M derived: sum of 3 quarters · filed 2019-08-13 | $2.20M derived: sum of 4 quarters · filed 2019-08-13 |
| 2018-03-31 | $1.03M 10-Q · filed 2019-05-14 | $2.22M derived: sum of 2 quarters · filed 2019-05-14 | $1.03M derived: sum of 3 quarters · filed 2019-05-14 | $2.22M derived: sum of 4 quarters · filed 2019-05-14 |
| 2017-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $2.00K derived: sum of 2 quarters · filed 2019-03-01 | $1.19M derived: sum of 3 quarters · filed 2019-03-01 | $2.22M 10-K · filed 2019-03-01 |
| 2017-09-30 | -$1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $5.00K derived: sum of 2 quarters · filed 2018-11-09 | $1.04M 10-Q · filed 2018-11-09 | $1.65M derived: sum of 4 quarters · filed 2018-11-09 |
| 2017-06-30 | $1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | $2.22M 10-Q · filed 2018-08-10 | $2.83M derived: sum of 3 quarters · filed 2018-08-10 | $2.00M derived: sum of 4 quarters · filed 2018-08-10 |
| 2017-03-31 | $1.03M 10-Q · filed 2018-05-11 | $1.65M derived: sum of 2 quarters · filed 2018-05-11 | $810.00K derived: sum of 3 quarters · filed 2018-05-11 | $2.29M derived: sum of 4 quarters · filed 2018-05-11 |
| 2016-12-31 | $614.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-30 | -$221.00K derived: sum of 2 quarters · filed 2018-03-30 | $1.25M derived: sum of 3 quarters · filed 2018-03-30 | $2.22M 10-K · filed 2018-03-30 |
| 2016-09-30 | -$835.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $640.00K derived: sum of 2 quarters · filed 2017-11-09 | $1.61M 10-Q · filed 2017-11-09 | $2.32M derived: sum of 4 quarters · filed 2018-03-30 |
| 2016-06-30 | $1.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $2.44M 10-Q · filed 2017-08-10 | $3.16M derived: sum of 3 quarters · filed 2018-03-30 | $3.83M derived: sum of 4 quarters · filed 2018-03-30 |
| 2016-03-31 | $968.00K 10-Q · filed 2017-05-22 | $1.68M derived: sum of 2 quarters · filed 2018-03-30 | $2.36M derived: sum of 3 quarters · filed 2018-03-30 | $3.01M derived: sum of 4 quarters · filed 2018-03-30 |
| 2015-12-31 | $715.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-30 | $1.39M derived: sum of 2 quarters · filed 2018-03-30 | $2.04M derived: sum of 3 quarters · filed 2018-03-30 | $2.67M 10-K · filed 2018-03-30 |
| 2015-09-30 | $676.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $1.32M derived: sum of 2 quarters · filed 2016-11-10 | $1.96M 10-Q · filed 2016-11-10 | $2.59M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-06-30 | $648.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $1.28M 10-Q · filed 2016-08-11 | $1.91M derived: sum of 3 quarters · filed 2017-03-10 | |
| 2015-03-31 | $632.00K 10-Q · filed 2016-05-13 | $1.26M derived: sum of 2 quarters · filed 2017-03-10 | ||
| 2014-12-31 | $630.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | $1.60M 10-K · filed 2017-03-10 | ||
| 2014-09-30 | $972.00K 10-Q · filed 2015-11-13 | |||
| 2013-12-31 | $152.00K 10-K · filed 2016-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |